Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Depreciation & Amortization (CF): 2023-2025

Historic Depreciation & Amortization (CF) for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to $19,000.

  • Compass Therapeutics' Depreciation & Amortization (CF) fell 86.71% to $19,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $399,000, marking a year-over-year decrease of 34.59%. This contributed to the annual value of $589,000 for FY2024, which is 15.74% down from last year.
  • Compass Therapeutics' Depreciation & Amortization (CF) amounted to $19,000 in Q3 2025, which was down 81.00% from $100,000 recorded in Q2 2025.
  • Over the past 5 years, Compass Therapeutics' Depreciation & Amortization (CF) peaked at $194,000 during Q1 2023, and registered a low of $19,000 during Q3 2025.
  • Over the past 3 years, Compass Therapeutics' median Depreciation & Amortization (CF) value was $152,000 (recorded in 2024), while the average stood at $140,636.
  • Data for Compass Therapeutics' Depreciation & Amortization (CF) shows a maximum YoY tumbled of 86.71% (in 2025) over the last 5 years.
  • Over the past 3 years, Compass Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $161,000 in 2023, then dropped by 13.04% to $140,000 in 2024, then tumbled by 86.71% to $19,000 in 2025.
  • Its last three reported values are $19,000 in Q3 2025, $100,000 for Q2 2025, and $140,000 during Q1 2025.